Hypercalcemia of Malignancy: An Update on Pathogenesis and Management

Overview

Journal N Am J Med Sci

Specialty General Medicine

Date 2015 Dec 30

PMID 26713296

Citations 92

Authors

Aibek E Mirrakhimov

Affiliations

Soon will be listed here.

Abstract

Hypercalcemia of malignancy is a common finding typically found in patients with advanced stage cancers. We aimed to provide an updated review on the etiology, pathogenesis, clinical presentation, and management of malignancy-related hypercalcemia. We searched PubMed/Medline, Scopus, Embase, and Web of Science for original articles, case reports, and case series articles focused on hypercalcemia of malignancy published from 1950 to December 2014. Hypercalcemia of malignancy usually presents with markedly elevated calcium levels and therefore, usually severely symptomatic. Several major mechanisms are responsible for the development of hypercalcemia of malignancy including parathyroid hormone-related peptide-mediated humoral hypercalcemia, osteolytic metastases-related hypercalcemia, 1,25 Vitamin D-mediated hypercalcemia, and parathyroid hormone-mediated hypercalcemia in patients with parathyroid carcinoma and extra parathyroid cancers. Diagnosis should include the history and physical examination as well as measurement of the above mediators of hypercalcemia. Management includes hydration, calcitonin, bisphosphonates, denosumab, and in certain patients, prednisone and cinacalcet. Patients with advanced underlying kidney disease and refractory severe hypercalcemia should be considered for hemodialysis. Hematology or oncology and palliative care specialists should be involved early to guide the options of cancer targeted therapies and help the patients and their closed ones with the discussion of comfort-oriented care.

Citing Articles

Successful Treatment of Methotrexate-associated Lymphoproliferative Disorder with the Pola-R-CHP Regimen.

Seki H, Morita K, Yamazaki S, Kurokawa M Intern Med. 2025; 64(1):123-127.

PMID: 39757000 PMC: 11781930. DOI: 10.2169/internalmedicine.3634-24.

Diffuse Large B-Cell Lymphoma Presenting With Hypercalcemia.

Hegazy Y, Chung M, Zamora N, Lee H, Ghallab M Cureus. 2024; 16(11):e73642.

PMID: 39677199 PMC: 11645462. DOI: 10.7759/cureus.73642.

Treatment Outcomes of Hypercalcemia of Malignancy Among Advanced Cancer Patients Attending Palliative Care Unit of a Tertiary Care Hospital in Bangladesh: An Observational Study.

Rouf R, Bhuiyan A, Alam A, Chowdhury M Health Sci Rep. 2024; 7(12):e70247.

PMID: 39669186 PMC: 11635692. DOI: 10.1002/hsr2.70247.

Uncovering Hypercalcemia of Malignancy Following Parathyroidectomy for Hyperparathyroidism.

Nessa L, Enabi J, Gonuguntla S, Modi B, Faheem M, Reddy A JCEM Case Rep. 2024; 2(12):luae203.

PMID: 39544891 PMC: 11561904. DOI: 10.1210/jcemcr/luae203.

Intraoperative Discovery of Lymphoma in the Knee During a Total Knee Arthroplasty: A Case Report.

Cha M, Kubsad S, Haft M, Levin A, Nikkel L Cureus. 2024; 16(8):e67943.

PMID: 39328599 PMC: 11426941. DOI: 10.7759/cureus.67943.

References

Strodel W, Thompson N, Eckhauser F, Knol J . Malignancy and concomitant primary hyperparathyroidism. J Surg Oncol. 1988; 37(1):10-2. DOI: 10.1002/jso.2930370104. View

Soyfoo M, Brenner K, Paesmans M, Body J . Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence. Support Care Cancer. 2012; 21(5):1415-9. DOI: 10.1007/s00520-012-1683-5. View

Hussain N, Khan M, Natarajan A, Mohammedabdul M, Mustafa U, Yedulla K . A case of multiple myeloma coexisting with primary hyperparathyroidism and review of the literature. Case Rep Oncol Med. 2013; 2013:420565. PMC: 3600291. DOI: 10.1155/2013/420565. View

LAFFERTY F . Differential diagnosis of hypercalcemia. J Bone Miner Res. 1991; 6 Suppl 2:S51-9; discussion S61. DOI: 10.1002/jbmr.5650061413. View

Gasparyan A, Ayvazyan L, Blackmore H, Kitas G . Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011; 31(11):1409-17. DOI: 10.1007/s00296-011-1999-3. View

Gurney H, Grill V, Martin T . Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet. 1993; 341(8861):1611-3. DOI: 10.1016/0140-6736(93)90756-7. View

Endres D . Investigation of hypercalcemia. Clin Biochem. 2012; 45(12):954-63. DOI: 10.1016/j.clinbiochem.2012.04.025. View

Wisneski L . Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int. 1990; 46 Suppl:S26-30. DOI: 10.1007/BF02553290. View

Hu M, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W . Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014; 99(9):3144-52. PMC: 4154084. DOI: 10.1210/jc.2014-1001. View

10.

Hosking D, Cowley A, Bucknall C . Rehydration in the treatment of severe hypercalcaemia. Q J Med. 1981; 50(200):473-81. View

11.

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

12.

Ling P, AHern R, Hardy J . Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer. 1995; 72(1):206-9. PMC: 2034143. DOI: 10.1038/bjc.1995.304. View

13.

Lins L . Reversible renal failure caused by hypercalcemia. A retrospective study. Acta Med Scand. 1978; 203(4):309-14. DOI: 10.1111/j.0954-6820.1978.tb14879.x. View

14.

Trimarchi H, Lombi F, Forrester M, Elizondo C, Sawinski D, Pereyra H . Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient. Nat Clin Pract Nephrol. 2006; 2(8):459-63. DOI: 10.1038/ncpneph0248. View

15.

Bech A, de Boer H . Denosumab for tumor-induced hypercalcemia complicated by renal failure. Ann Intern Med. 2012; 156(12):906-7. DOI: 10.7326/0003-4819-156-12-201206190-00026. View

16.

Wong K, Tsuda S, Mukai R, Sumida K, Arakaki R . Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia. Endocrine. 2005; 27(1):83-6. DOI: 10.1385/ENDO:27:1:083. View

17.

Saad F, Brown J, Van Poznak C, Ibrahim T, Stemmer S, Stopeck A . Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2011; 23(5):1341-1347. DOI: 10.1093/annonc/mdr435. View

18.

Akhtari M, Mansuri J, Newman K, Guise T, Seth P . Biology of breast cancer bone metastasis. Cancer Biol Ther. 2007; 7(1):3-9. DOI: 10.4161/cbt.7.1.5163. View

19.

Lee S, Kim B, Bae M, Yi Y, Kim W, Jeon Y . Concurrence of primary hyperparathyroidism and metastatic breast carcinoma affected a parathyroid gland. J Clin Endocrinol Metab. 2013; 98(8):3127-30. DOI: 10.1210/jc.2013-1227. View

20.

Diercks D, Shumaik G, Harrigan R, Brady W, Chan T . Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med. 2004; 27(2):153-60. DOI: 10.1016/j.jemermed.2004.04.006. View